MedTrace Logo

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

NCT04989322 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-12-08

No results posted yet for this study

Summary

Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

Conditions

  • Nsclc
  • EGFR Activating Mutation
  • EGF-R Positive Non-Small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • ROS1 Gene Rearrangement
  • ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

200 mg Q3W

DRUG

Lenvatinib

8 mg daily

DRUG

Pemetrexed

500 mg/m2 Q3W

DRUG

Carboplatin

AUC5 Q3W

Sponsors & Collaborators

  • Dr Joanne CHIU

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2024-08-31
Completion
2024-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989322 on ClinicalTrials.gov